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Abstract 
Zika virus (ZIKV) infection during pregnancy may cause diverse and serious congenital defects 
in the developing fetus. In this study, we utilized pregnant guinea pigs to study congenital Zika 
syndrome. Female guinea pigs early in pregnancy (weeks 3–4 of gestation) were inoculated with 
Asian ZIKV strain (PRVABC59) or PBS (mock) via subcutaneous route. Dams were weighed 
daily, and blood and urine were collected at regular intervals to assess the presence of virus. 
Weight loss was observed in ZIKV-infected dams during first week of the infection. ZIKV-
infected animals seroconverted with significant viremia and viral secretion in the urine. During 
the period between infection and delivery of the pups, significant viral RNA and NS1 protein 
were detected in all animals from 2 to 5 days after infection, with peak viral replication at day 3. 
We also detected robust viral RNA shedding in urine, with a prolonged duration relative to that 
of viremia. Dams developed remarkably robust ZIKV-specific neutralizing antibody response, 
and anti-ZIKV antibodies were also recovered from pups. Notably, ZIKV was efficiently 
transmitted from infected guinea pigs to their naïve co-caged mates. ZIKV infection of pregnant 
guinea pigs caused fetal damage. Sixty percent of ZIKV-infected dams showed abnormal 
pregnancies in that they all delivered at least one or more abnormal pup. Pups from ZIKV-
infected animals exhibited significant intrauterine growth retardation. ZIKV was detected in the 
brain of pups from ZIKV-infected animals. ZIKV RNA and anti-ZIKV antibody levels in the 
dams reliably predicted abnormalities in pups. ZIKV detection in the brain tissues correlated 
with the pup abnormalities. In conclusion, the pregnant guinea pig model provides quantifiable 
 iii 
congenital abnormality readouts to assess pregnancy outcomes; and may serve as a good model 
to test therapeutics, and to elucidate the mechanisms of ZIKV congenital pathogenesis. 
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Chapter I. 
Background 
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1.1 Zika Virus 
i. History and Epidemiology 
Zika Virus (ZIKV) is a mosquito-borne Flavivirus, belonging to the family 
Flaviviridae. ZIKV was first discovered in 1947 in Uganda’s Zika forest in the blood 
of a febrile monkey, as well as in crushed suspensions of the Aedes mosquito [1]. 
Following this discovery, only a few human cases appeared, restricted to Africa and 
Asia. However, in 2007, the first human outbreak of ZIKV occurred in Micronesia, 
specifically on the island of Yap. The strain that caused this outbreak was the Asian 
strain. The virus continued to spread across the Pacific Islands, causing another 
outbreak from 2013-2014 in the French Polynesia. The most recent outbreak began in 
March 2015 in the state of Rio Grande do Norte, Northeast Brazil. By the end of 2015 
there were ~1,300,000 suspected cases in Brazil alone. The virus continued to spread 
throughout South and Central America, to then reach the lower parts of North 
America [1]. The United States, including Hawai῾i has confirmed a few travel related 
cases of ZIKV-associated disease, as well as other countries in Europe [2-4]. 
Following the outbreak in Brazil, it was apparent that transmission may occur in ways 
other than by the Aedes mosquito [1, 5]. Since ZIKV is a blood-borne pathogen, the 
virus was found in donor blood, leading to transmission by transfusion [1, 5]. 
Beginning in February 2016, the Food and Drug Administration (FDA) required that 
any areas in the United States, as well as Puerto Rico, with ZIKV transmission should 
stop blood donations, with the exception that the blood bags are tested for the virus 
using Nucleic Acid Amplification Testing (NAT) or they are treated with pathogen-
reduction technology [6].  
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There have also been multiple cases of sexual transmission from male to female. 
After returning from trips to areas with ZIKV, the sexual partners who had not been 
naturally exposed show positive for the virus in their blood [1]. Semen samples of 
infected males have been tested positive for Zika viral RNA with some cases at levels 
100,000 times that of matched blood or urine samples [1, 7]. The viral RNA remains 
present in the semen for 10 weeks after the onset of Zika-like symptoms [1, 8]. 
Studies have shown that Zika virus RNA in the semen can persist for much longer 
periods than other bodily fluids. One man in his 30’s became infected and on day 91 
after the onset of symptoms, ZIKV was detected in urine, saliva and semen samples 
using RT-PCR; but on day 134, his semen sample still gave a positive result while the 
urine and saliva were negative [9].  
ZIKV is also transmitted perinatally. A study conducted on 345 pregnant women 
during the Zika outbreak in Brazil [10] indicated that 53% of the pregnant women 
were positive for ZIKV by PCR. The pregnancy outcome was available for 125 of 
these women who were tested positive for ZIKV, with 116 of these women gave live 
birth and 9 had fetal death. Additionally, there were 5 miscarriages during the first 
trimester, 2 during the second, and 2 stillbirths during the third trimester. A 
disproportionally high percentage (9%) of these live births from ZIKV positive 
mothers were small in size for their gestational age. This may have been due to fetal 
growth restriction or poor placental perfusion. Additionally, four infants exhibited 
microcephaly at birth [10]. 
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ii. Virology 
ZIKV is part of the Flavivirus genus in the Flaviviridae family, along with other 
viruses including West Nile virus (WNV), Dengue virus (DENV) and Yellow Fever 
virus (YFV) [1, 11]. These viruses are closely related as can be seen in Figure 1, 
which also shows the various Asian and African strains of ZIKV [12]. Flaviviruses 
are enveloped viruses, which contain a positive sense single stranded RNA genome 
that is approximately 11kb in length [1], seen in Figure 3. [13]. The RNA encodes for 
3 structural and 7 nonstructural proteins. The structural proteins, the capsid (C), the 
envelope (E) and the membrane (prM/M) proteins, are integral components of the 
virion particle, while the nonstructural (NS) proteins, NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5, have other roles including immune evasion and viral 
replication [1, 13]. 
 
Figure 1. Zika virus phylogenetic tree showing the African and Asian lineages [12]. 
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iii. Life cycle and Replication 
ZIKV is an arbovirus, meaning the virus is transmitted primarily through arthropods, 
including mosquitoes [1]. The mosquito that carries ZIKV is the Aedes species, 
specifically A. aegypti and A. albopictus, as well as A. africanus, which was the first 
mosquito species in which ZIKV was discovered. There are two life cycles of ZIKV 
virus, the first being maintained between the mosquito and non-human primates, the 
sylvatic cycle, and the second, in which humans become infected, the urban cycle 
[14].  Once the virus is in the salivary glands of the mosquito and the mosquito takes 
a blood meal from a human, the virus is then transmitted into the blood stream of the 
human. The cycle may continue by the mosquito taking another blood meal, ingesting 
the virus, or the virus may be transmitted person-to-person in the ways described 
before, perinatally, sexually, or by blood transfusion [14].  
Following human infection the virus is able to enter cells through receptor-mediated 
endocytosis and fuses its membrane to the endosome (Figure 2) [14]. The viral RNA 
is released into the cytoplasm of the host cell due to an acidic-pH-triggered 
mechanism. Transcription of the positive sense single stranded genomic RNA begins, 
resulting in the synthesis of the three structural and seven nonstructural proteins. 
Assembly of the virus takes place at the ER membrane [14], forming immature 
virions (Figure 3) [13]. The immature virions leave the ER, pass through the Golgi, to 
reach the trans-Golgi network (TGN) where the acidic pH results in cleavage of the 
prM protein by the cellular protease, furin. Cleavage of prM results in the dissociation 
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of the pr segment, generating mature virions that exit the host cell by exocytosis [14]. 
Many mature viruses are now able to continue infection and replication of new cells. 
 
 
Figure 2. Zika virus replication cycle [15]. 
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Figure 3. Zika virus structure of mature (top) and immature (bottom) virions [13]. 
iv. ZIKV Clinical Disease 
Approximately 80% of individuals infected with ZIKV are asymptomatic; however, 
symptoms that may occur include mild febrile illness that is characterized by fever, 
rash, arthralgia, myalgia, headache, and conjunctivitis [12, 16]. Prior to the 2015-
2016 outbreak in the Americas, these were the only known clinical presentations of 
the disease. However, during these recent outbreaks, there was an increased 
association between ZIKV infection and fetal abnormalities, such as congenital 
microcephaly [12, 17, 18]. These fetal abnormalities are what is termed as Congenital 
Zika Syndrome (CZS). The clinical presentation of CZS includes both structural and 
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functional components. The structural components include cranial morphology, brain 
anomalies, ocular anomalies, and congenital contractures, while the functional 
components are due to neurologic impairments. The underdeveloped brain results in 
extreme craniofacial disproportioning, including a depression of the frontal and 
parietal bones collectively known as microcephaly. There has also been evidence of 
intracranial calcifications, typically in the subcortical region of the brain. This 
calcification is likely resulted from cell death caused by necrosis or apoptosis. Cell 
death and cell injury is also the cause of central nervous system damage [18]. 
v. ZIKV in the brain 
The increased association of microcephaly with ZIKV infection of pregnant women is 
one of the largest concerns of public health officials. Many experiments have been 
completed to analyze the presence of the virus in the brain, how it crosses the BBB, 
and which cell type(s) it is infecting. Studies on neonates with CZS [19, 20] and 
ZIKV infected non-human primate fetuses [21, 22] have observed ZIKV in the brain 
tissue. An in vitro model suggests that the virus is able to cross the BBB through the 
processes of induced brain endothelial cell (i-BEC) infection, transcellular passage, 
and subsequent viral release on the other side of the monolayer [23]. The virus then 
binds to the AXL receptor on cells such as neural progenitor cells (i-NP) and mature 
neurons (i-Ns). Infection of these cells results in cell death and cell damage, 
preventing proper development of the brain and central nervous system of fetuses 
[22]. 
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vi. Therapeutics and Vaccines 
Unfortunately, there are currently no licensed therapeutics or vaccines available for 
ZIKV infection. However, according to the WHO, there are 15 vaccines currently in 
Phase I clinical trials and one vaccine in Phase II trial [24]. While there is research 
progress in treatment or prophylaxis, successful development leading to product 
licensure is still many years away. 
2.1 Animal Models 
i. Importance of Animal Models 
Few animal models of ZIKV infection existed prior to the recent ZIKV epidemics. Only 
three studies tested the virus’ pathogenic potential in animal models between the time of 
the virus’ first isolation in 1947 and the epidemic in 2015 [25-27]. Without the use of a 
reliable animal model, our understanding of ZIKV infection and pathogenesis, as well as 
development of vaccines and/or treatments, will be significantly hampered. While there 
are many animal models available such as mice, non-human primates, and guinea pigs, 
they each have their advantages and disadvantages. Using the model that mimics human 
disease the most with as little to no manipulation and is easy and inexpensive to house is 
ideal.  
ii. Mouse Model 
In one study, ZIKV was inoculated via intracranial route in mice, causing neurological 
disease in suckling or adult mice [27]. However, infection with ZIKV via intraperitoneal 
route in adult immunocompetent mice did not cause disease, indicating that intracranial 
route of inoculation is necessary for successful infection. 
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Recently, several groups have also examined immunocompromised adult mice in order to 
develop a successful mouse model that can support ZIKV replication and disease. Most 
of these models are deficient in interferon (IFN) response, which is an important 
component during antiviral defense. These animals developed severe ZIKV disease 
including paralysis, hind-limb weakness and death after peripheral inoculation. Older 
immunocompromised mice (11 week-old) are less susceptible to infection than the 
younger immunocompromised mice (3-5 week-old) [28, 29]. While immunodeficient 
mice are useful in ZIKV studies, they are inherently biased toward producing disease 
based on their genetic background. Additionally, lethality is the main endpoint without 
assessing actual clinical disease.  
iii. Non-Human Primate Model 
Non-human primates are another common animal model to use due to their anatomical 
and physiological similarities to humans [30]. This animal model allows for successful 
ZIKV infection without the use of immunological manipulation. There have been a few 
studies using rhesus macaques to elucidate ZIKV pathogenesis [20, 21]. However, non-
human primates require large facilities that are not readily available to many institutions. 
Furthermore, the cost of animal purchase and husbandry requirements are significantly 
higher than those for small animal (rodent) models. 
iv. Other Animal Models 
Other animal models that have been used for ZIKV studies include hamsters and pigs. 
Hamsters are similar to mice in that they are small in size and easy to handle. However, 
in order for ZIKV to cause disease, these animal hosts must be rendered partially 
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deficient in innate immunity. Accordingly, infection in STAT-2 knockout hamsters 
results in severe diseases in adult animals and fetuses [31]. While this study was 
successful in causing disease, using an immunologically manipulated model is not ideal 
and does not represent natural human infection. Pigs have similar litter size as mice and 
longer gestational period (approximately 114 day), which allow for adequate sample size 
and time window for congenital infection studies, such as analyzing CZS [32]. However, 
similar to non-human primates their housing/husbandry is a challenge in terms of costs 
and logistics. 
v. Guinea Pig Model 
An earlier study in 1952 had attempted to inoculate guinea pigs with the African ZIKV 
strain, MR766 via the intracranial route but the animals developed no signs of infection 
[27]. However, this strain had previously undergone extensive passaging in suckling 
mouse brains [33]. Recently, our group showed that guinea pigs are susceptible to 
infection by a contemporary Asian strain of ZIKV [34]. The guinea pigs were inoculated 
with the PRVABC59 strain via subcutaneous route resulting in clinical signs of infection 
including fever, lethargy, hunched back, ruffled fur, and decreased mobility. ZIKV was 
detected in the serum using qRT-PCR and plaque assays, and infection resulted in a 
dramatic increase in protein levels of multiple cytokines, chemokines and growth factors 
in the serum. ZIKV RNA was detected in tissues such as the spleen and brain [34]. 
Guinea pigs are more physiologically and immunologically similar to humans than other 
small animals, including mice. Further, guinea pigs are a well-accepted model for 
congenital infections and sexual transmission [35, 36]. The guinea pig’s reproductive 
physiology and estrous cycle are similar to humans. Also, placentation in the guinea pig 
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occurs in a similar manner to that of humans, with both guinea pig and human placentas 
classified as hemomonochorial [37]. Similar to humans, the placenta of guinea pigs has a 
single trophoblast layer that separates maternal and fetal circulations. They have a long 
gestation period and pups are born with a mature CNS. These similarities of guinea pigs 
to humans makes this species a promising animal model to study in utero transfer of 
ZIKV and its neurological manifestations in infants [36]. Similar to mice, guinea pigs are 
considered a small animal model; however, they do not require immunologic 
manipulation to establish infection and produce disease. 
vi. In utero animal models 
Table 1. Comparison of in utero animal models. 
 Guinea Pigs Mice Non-Human 
Primates (Rhesus) 
Swine Hamsters 
Cost of 
purchase 
~$100 ~$10 ~$50,000 ~$250 ~$50 
Size Small Small Large Large Small 
Gestation 
period 
59-72 days ~20 days ~164 days ~115 days ~22 days 
Placenta 
structure 
Hemomonochorial Hemotrichorial Hemomonochorial Epitheliochorial Hemotrichorial 
Does 
ZIKV 
cause 
disease? 
Yes No Yes Yes No 
 
Table 1 demonstrates a comparison of the various animal models commonly used for in 
utero ZIKV research. When comparing the various aspects for each animal model, the 
guinea pig model looks to be the best to use for in utero experiments, especially when 
infecting with ZIKV.  
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While the cost of purchase is reasonable for the small animal models, swine are a little 
more costly, especially if a large cohort is needed, and non-human primates are extremely 
expensive at a cost of approximately $50,000 for a single rhesus macaque.  
The smaller the size of an animal model, the less space they need for housing, which 
means cheaper daily costs. While guinea pigs are larger than mice and hamsters, they are 
still considered a small animal model. Non-human primates and swine on the other hand, 
are large and need a lot of housing space, which most facilities do not have and for those 
that do, the cost per day to house and care for the animals is quite high.  
The gestation period is an important aspect to account for when planning an in utero 
experiment because it can determine how quick the results will be determined, the cost 
will increase with the longer gestation periods due to the daily husbandry charges. Most 
importantly, the longer gestation periods corresponds to the stage of development the 
animals are at, at the time of birth. For mice and hamsters, who have shorter gestation 
periods, the pups are born without a developed CNS. The longer gestation periods, such 
as that for guinea pig pups, they will be born with a developed CNS. Animals born 
without a developed CNS will continue development for about 21 days following birth, 
delaying some experiments until they are developed enough to examine, as well as not 
representing human babies who are born with a developed CNS. 
Animals vary in their reproductive system, specifically in the structure of their placenta. 
Humans have a hemomonochorial structure, meaning they have a single trophoblast layer 
separating the maternal and fetal circulations. Similarly, Guinea pigs and non-human 
primates also have a hemomonochorial placenta. However, mice and hamsters have a 
hemotrichorial placenta structure meaning they have three trophoblast layers as opposed 
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to one. Swine have a different placenta than all of these animal models. They have an 
epitheliochorial placenta, in which the chorion is next to the lining of the uterus but does 
not invade or erode the lining. Since humans have a hemomonochorial, guinea pigs and 
non-human primates would mimic humans for in utero experiments. 
Since this study is analyzing CZS, ZIKV replication within the animal models is another 
important aspect to consider. As described above, ZIKV is not able to replicate and cause 
disease in mice and hamsters. They must first go through immunologic manipulation, 
which is an additional cost to the project. Studies have shown that the virus is able to 
replicate and cause disease in guinea pigs, non-human primates, and swine that are not 
immunologically manipulated. 
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Chapter II. 
Thesis Scope 
 
  
  
16 
1.1 Objective, Hypothesis and Rationale: 
The objective of the proposed research is to characterize and utilize the guinea pig model to 
study in utero ZIKV infection. With this model, we will examine the relationship between 
clinical disease and the derangements observed in the immune system, the nervous system 
and viral load. Our central hypothesis is that the guinea pigs will develop ZIKV disease, and 
transmit virus to fetus after subcutaneous inoculation of ZIKV in mothers. 
2.1 Innovation and Significance: 
The proposed research is highly innovative as it will be the first study to employ the guinea 
pig model to characterize in utero transmission and pathogenesis of ZIKV. The findings from 
this study will have a significant impact on understanding the mechanisms associated with 
ZIKV transmission to the fetus, pregnancy outcomes, pathogenesis of sexual transmission, 
short- and long-term neurological sequelae in infants, and other manifestations in infants 
including developmental delays and physical disorders. This study will help understand the 
pathogenic mechanisms underlying the development of ZIKV associated neurological 
disease. Also, this model system will form the basis to understand the basic biology of ZIKV 
infection and disease, and to develop strategies to prevent transmission of ZIKV to the fetus, 
and for evaluating vaccines and therapeutics. 
3.1 Specific Aims: 
Specific Aim 1: 
Inoculate pregnant guinea pigs with ZIKV via subcutaneous route and examine clinical 
signs and pregnancy outcomes. 
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Specific Aim 2: 
Examine the kinetics of infection and immune response in pregnant guinea pigs. 
Specific Aim 3: 
Evaluate the presence of ZIKV in the fetuses, and the effects of ZIKV infection on fetal 
loss, intrauterine development of the fetuses and brain injury.  
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Chapter III. 
Congenital Zika Syndrome in Guinea Pigs 
 
 
 
 
  
19 
Abstract 
Zika virus (ZIKV) infection during pregnancy may cause diverse and serious congenital defects 
in the developing fetus. In this study, we utilized pregnant guinea pigs to study congenital Zika 
syndrome. Female guinea pigs early in pregnancy (weeks 3–4 of gestation) were inoculated with 
Asian ZIKV strain (PRVABC59) or PBS (mock) via subcutaneous route. Dams were weighed 
daily, and blood and urine were collected at regular intervals to assess the presence of virus. 
Weight loss was observed in ZIKV-infected dams during the first week of infection. ZIKV-
infected animals seroconverted and significant viral secretion in serum and urine was detected. 
During the period between infection and delivery of the pups, significant viral RNA and NS1 
protein were detected in all animals from 2 to 5 days after infection, with peak viral replication at 
day 3. We also detected robust viral RNA shedding in urine, with a prolonged duration relative 
to that of viremia. Dams developed remarkably robust ZIKV-specific neutralizing antibody 
response, and anti-ZIKV antibodies were also detected in pups. Notably, ZIKV was efficiently 
transmitted from infected guinea pigs to their naïve co-caged mates. ZIKV infection of pregnant 
guinea pigs caused fetal damage. Sixty percent of ZIKV-infected dams showed abnormal 
pregnancies in that they all delivered at least one or more abnormal pup. Pups from ZIKV-
infected animals exhibited significant intrauterine growth retardations. ZIKV was detected in the 
brain of pups from ZIKV-infected animals. ZIKV RNA and anti ZIKV-antibody levels in the 
dams reliably predicted abnormalities in pups. ZIKV detection in the brain tissues correlated 
with the pup abnormalities. In conclusion, the pregnant guinea pig model provides quantifiable 
congenital abnormality readouts to assess fetal outcome and may serve as a good model to test 
therapeutics, and to study the mechanisms of ZIKV congenital pathogenesis. 
  
20 
 
Background 
Zika virus (ZIKV) is a mosquito-borne Flavivirus, belonging to the family Flaviviridae, along 
with other viruses including West Nile virus (WNV), Dengue virus (DENV) and Yellow Fever 
virus (YFV) [1, 2]. ZIKV was first discovered in 1947 in Uganda’s Zika forest in the blood of a 
febrile monkey, as well as in crushed suspensions of the Aedes sp. mosquito. Following this 
discovery, only a few human cases appeared, restricted to Africa and Asia. However, in 2007, 
the first human outbreak of ZIKV occurred in Micronesia, specifically on the island of Yap. The 
most recent outbreak began in March 2015 in the state of Rio Grande do Norte, Northeast Brazil. 
The virus continued to spread throughout South and Central America, to then reach the lower 
parts of North America [1]. The United States, including Hawai῾i, has confirmed a few travel 
related cases of ZIKV-associated disease, as in several European countries [3-5]. 
ZIKV is an arbovirus, meaning the virus is transmitted primarily through arthropods, including 
mosquitoes [6]. However, following the 2015 outbreak in the Americas, there has been evidence 
of congenital transmission, as well as sexual and blood transfusion transmission [1, 6]. 
Symptoms of ZIKV may include a “Zika” rash as well as mild flu-like symptoms such as fever, 
headache, myalgia, and occasionally conjunctivitis [6, 7]. Prior to the 2015 outbreak these 
symptoms were characteristic of the disease. However, during the outbreak, fetal complications 
occurred including what is known as Congenital Zika Syndrome (CZS) [6, 8, 9]. If a pregnant 
woman were to become infected with ZIKV during pregnancy, especially during the first 
trimester, she has about a 7% chance of having a miscarriage, stillbirth or a baby born with CZS. 
CZS is characterized by severe microcephaly with partial collapsed skull, decreased brain tissue 
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and brain damage, ocular scarring and damage, as well as hypertonia restricting body movement 
soon after birth [9].    
Few animal models of ZIKV infection existed prior to the recent ZIKV epidemics. Only three 
studies tested the virus’ pathogenic potential in animal models between the time of the virus’ 
first isolation in 1947 and the 2015 epidemic [10, 11]. These animal models all used mice; 
however, ZIKV is unable to produce disease in immunocompetent mice. In order to study the 
evolution of ZIKV infection and pathogenesis, mice must render deficient in one or more 
components of innate immune responses by genetic ablation, such as the Ifnar1-/- knockout mice 
[12, 13].  Thus, while these types of mouse model are readily available, they are not ideal.  
Non-human primates are also a common animal model to use due to their anatomical and 
physiological similarities to humans [14]. This animal model allows for successful ZIKV 
infection without the use of immunologic manipulation. There have been a few recent studies 
using rhesus macaques to better understand ZIKV pathogenesis. However, non-human primates 
require large facilities that are not readily available at many research institutions. Additionally, 
the cost of purchase as well as the proper housing requirements are significantly higher than 
small animal models. 
Guinea pigs are more physiologically and immunologically similar to humans than other small 
animals, including mice. Guinea pigs are a well-accepted model for a number of human infection 
and disease processes, including congenital infections and sexual transmission [15, 16]. The 
guinea pig’s reproductive physiology and estrous cycle are similar to humans. Also, placentation 
in the guinea pig occurs in a similar manner to that of humans, and both guinea pig and human 
placentas are classified as hemomonochorial [17]. Similar to humans, the placenta of guinea pigs 
has a single trophoblast layer that separates maternal and fetal circulations. They have a long 
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gestation period and pups are born with a mature CNS. These similarities of guinea pigs to 
humans make this species a promising surrogate model for studies of in utero transfer of ZIKV 
and neurological manifestations in infants [16].  
In an earlier study, inoculation of guinea pigs via the intracranial route with the African ZIKV 
strain MR 766 produced on infection [11]. However, the strain used had undergone extensive 
passaging in suckling mouse brains. Recently, it was shown by our group and others that guinea 
pigs are susceptible to infection by a contemporary Asian strain of ZIKV [18, 19]. The guinea 
pigs were inoculated with the PRVABC59 strain via the subcutaneous route and results in 
clinical signs of infection, which include fever, lethargy, hunched back, ruffled fur, and 
decreased mobility. ZIKV was detected in the serum using qRT-PCR and plaque assays and 
infection resulted in a dramatic increase in protein levels of multiple cytokines, chemokines and 
growth factors in the serum. ZIKV RNA was also detected in the spleen and brain [18]. 
 Materials and Methods 
Animals: Hartley guinea pigs were purchased from Charles River Laboratory (Wilmington, 
Massachusetts, United States). This study was approved by the University of Hawaii Institutional 
Animal Care and Use Committee (IACUC), and conducted in strict accordance with guidelines 
established by the National Institutes of Health and the University of Hawaii IACUC.  
Mating: 3-4 week old guinea pigs were purchased from Charles River. We received 14 males 
and 14 females of the same age from separate litters to ensure no inbreeding. Once the females 
were sexually mature one female and one male were housed together to mate. Females were 
  
23 
weighed daily and checked for signs of pregnancy, which included analyzing the vaginal 
membrane for the mucous plug.  
Serum separation: After whole blood collection, the samples were placed at room temperature 
for 1 hour, then placed on ice. The samples were then centrifuged for 15 minutes at 10,000 rpm 
to allow separation of the serum. Serum was then aliquoted and stored at -80°C until needed for 
experiments. 
Progesterone ELISA: After one week of pairing, 25 μL of serum from each female on a weekly 
interval was used to analyze progesterone levels. The Human Progesterone ELISA Kits used for 
this analysis were purchased from DRG (Cat# EIA1561). Once the progesterone levels reached 
above 20 ng/mL, the female guinea pigs were confirmed pregnant.  
ZIKV Infection: ZIKV strain PRVABC59 (BEI Resources) was used in this study. At 3-4 
weeks after conception, nine female guinea pigs were subcutaneously inoculated with either 
1x106 PFU sequence-verified Puerto Rico ZIKV strain and five were inoculated with PBS as the 
mock infection group. Following infection, guinea pigs were observed daily for the next 7 days, 
then weekly until birth, for signs of infection. Clinical signs included ruffled fur, hunched back, 
and skin tone. Body temperature was taken for signs of fever, and blood was collected to assess 
the presence of viremia and anti-ZIKV antibodies. 
NS1 ELISA: The presence of the NS1 protein in guinea pig serum samples was analyzed using 
the Zika virus NS1 ELISA kit (BioFront Technologies) following the manufacturer’s protocol 
(Cat# ZIKV-NS1-EK-96).  
RNA Extraction: Total RNA from guinea pig tissues was extracted using the RNeasy Mini Kit 
(Qiagen) following manufacturer’s protocol (Cat# 74106). About 200 mg of frozen tissue (brain, 
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spleen, kidney, and liver) was powdered over dry ice to obtain homogenous samples for total 
RNA extraction. 
Synthesis of cDNA from cellular RNA: One microgram of cDNA was synthesized from 1 μg 
of cellular RNA using iScript Select cDNA Synthesis Kit (Bio-Rad Cat# 170-8896) following 
manufacturer’s procedures. In brief, reaction mix, reverse transcriptase and RNA template were 
mixed to a final reaction volume of 20 μL by adding nuclease-free water.  The reaction mixtures 
were incubated at 42°C for 45 min, followed by 85°C for 5 min to heat-inactivate the reverse 
transcriptase.  
Table 1. Primer sequences used for qRT-PCR 
Gene Primer sequence (5’-3’) Amplicon  
(bp)   Tm (°C) 
ZIKV Primer 
Forward 1086 
Reverse 1162c 
 
CCGCTCCCCAACACAAG 
CCACTAACGTTCTTTTGCAGACAT 
 
17       57.4 
24       55.8 
 
qRT-PCR: Fold-changes in the ZIKV viral RNA were determined by real-time qRT-PCR. Less 
than 1000 ng (maximum amount stated by manufacturer’s protocol) of cDNA was used as 
template for real-time PCR assays with the ZIKV primers listed in Table 1. Standard curves were 
generated using RNA extracted from previously titrated ZIKV dilutions. The cDNA templates 
and the primers were combined with the iQ Supermix (Bio-Rad Cat# 1725160) and used for 
PCR. PCR thermal cycling was initiated with a first denaturation step of 95°C for 15 min 
followed by 40 cycles of 94°C for 15 sec and 60°C for 1 min, and then brought down to 4°C for 
5 min.  
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Plaque Reduction Neutralization Test (PRNT): The serum titers of anti-ZIKV neutralizing 
antibodies were measured using the PRNT as described previously [20, 21]. Serum was collected 
from the dams daily for the first week after infection followed by weekly until the time of birth. 
Serum was also collected from the naïve co-caged mates, as well as the pups, at the time of 
euthanasia. The serum samples were diluted from 1:20 to 1:20,480 and PRNT was conducted 
against ZIKV PRVABC59 strain. The highest dilution of serum resulting in 50% reduction in the 
number of plaques compared to the growth of the virus control was determined as described 
previously [21]. 
ZIKV detection in pups brain using virus culture: About 150 mg of frozen brain tissue was 
homogenized using the bullet blender method. An equal amount of 0.5mm Zirconium beads was 
added to the tissue sample together with protease inhibitors. The mixture was placed in the bullet 
blender for 3 minutes at Speed 6. A 100 μL of the homogenate was used to infect Vero cells. The 
cell lysate and its supernatant were harvested 5 days later. The cell lysate was then used for qRT-
PCR while 100 μL of the supernatant was used for a second round of infection with fresh Vero 
cell cultures. Following the second round of infection, the cell lysate was collected once again 
and analyzed by qRT-PCR. 
Guinea pig pup size measurements: Within the first 24 hours after birth, the pups were 
weighed and measured to evaluate morphologically. The measurements that were taken included 
crow-rump length (CRL), indicated by the blue line; occipitofrontal (OF) diameter, indicated by 
the green line; and the head circumference, indicated by the purple line. The CRL and OF 
measurements were then multiplied to determine the overall pup size. 
  
26 
  
Figure 1. Guinea pig pup measurements. Overall body size measured by the crown-rump 
length (blue) and the occipito-frontal diameter (green). The head circumference was measured 
using the diameter (purple). 
 
Results 
Pregnant guinea pigs are susceptible to ZIKV infection 
To determine whether ZIKV is infectious in guinea pigs, time-mated pregnant guinea pigs were 
infected with ZIKV or PBS (Mock). Nine dams were subcutaneously inoculated with 106 plaque-
forming units (PFU) of Asian ZIKV strain (PRVABC59). Five dams were inoculated with PBS 
(Mock). The guinea pigs were inoculated at 3-4 weeks of gestational age, equivalent to the end 
of the first trimester. Every day for the first week, followed by weekly until the end of the 
pregnancy, the guinea pigs were weighed and observed for clinical signs of disease including 
ruffled fur, hunched back, fever and weight loss.  
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All five pregnancies of mock-infected dams were normal. Five out of nine pregnancies were 
adversely affected after ZIKV infection, while four pregnancies were normal. Mock-infected 
dams gained between 400-500 g weight during the pregnancy (Figure 2). Weight loss was 
observed in five out of nine ZIKV-infected dams during the first week of infection. Total weight 
gain of these five ZIKV-infected dams during the pregnancy was only between 100-200g. The 
other four ZIKV-infected dams did not lose any significant weight during the first week of 
Figure 2. Weights of pregnant guinea pigs. Following infection, pregnant guinea pigs were 
weighed once a day for 1 week followed by once a week until they gave birth. Control guinea 
pigs (blue) showed a steady weight gain. ZIKV infected guinea pigs (red) showed a decrease 
during the first week after infection. 
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infection. Total weight gain in these four ZIKV-infected dams was similar to the mock-infected 
dams. No other clinical signs of illness, ruffled fur, hunched back, or fever, were observed in 
ZIKV-infected dams. Also, none of the infected dams showed clinical signs that met humane 
endpoints or spontaneously died of infection. 
Kinetics of infection and antibody response in pregnant dams 
Whole blood and serum were collected at regular intervals to assess the presence of viral RNA 
(Figure 3A), NS1 protein (Figure 3B), and anti-ZIKV antibodies (Figure 4). ZIKV-infected 
pregnant guinea pigs exhibit seroconversion and significant viral replication in the serum. ZIKV-
specific qRT-PCR detected viral RNA in the whole blood of all nine infected dams. Viral RNA 
was detected in all animals from 2 to 4 days after infection, with peak titers of 4.5 to 5.5 log 
RNA copies/mL at day 3 after infection. Only three infected dams had detectable viremia at day 
5. We also measured circulating levels of ZIKV NS1 protein in serum using ELISA. NS1 protein 
Figure 3. ZIKV detection in dams. (A) All infected female guinea pigs showed significant 
viral RNA in the whole blood at days 2 to 5 after infection as measured by qRT-PCR. (B) 
Circulating NS1 protein detected in the serum of infected guinea pigs using ELISA. 
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was detected in all nine animals at day 3 after inoculation. Similar to RNA, only three animals 
had detectable levels of NS1 at day 5. Two animals continued to have low levels of detectable 
NS1 until day 24 after inoculation. Notably, high and persistent viremia was observed in the 
dams that lost significant weight and had abnormal pregnancies. ZIKV was not detected in the 
serum of mock-infected animals.  
 
We next measured anti-ZIKV neutralizing antibody titer in the serum of infected animals using 
plaque reduction neutralization test (PRNT). Anti-ZIKV neutralizing antibodies were not 
detected in the serum of all five mock-infected dams. Infected dams developed a remarkably 
robust ZIKV-specific neutralizing antibody response as early as day 9 after infection and 
sustained thereafter (Figure 4a). Similar to the viremia, high antibody titers were observed in the 
dams that lost significant weight and had abnormal pregnancies. ZIKV was efficiently 
transmitted from infected female guinea pigs to naïve co-caged male animals (Figure 4b). All 
contact guinea pigs exhibited seroconversion.  
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Figure 4. ZIKV-specific antibody levels detected in dams and male guinea pigs using 
PRNT. ZIKV-specific antibodies detected in (A) infected dams beginning at day 9 after 
infection until the time of euthanasia, as well as, (B) the co-caged males at the time of 
euthanasia. 
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Congenital Zika syndrome in guinea pigs 
Within the first 24 hours of birth, individual fetuses were evaluated for morphological 
abnormalities, including weight, body size and head circumference by measuring the crown-
rump length (CRL) and the occipito-frontal (OF) diameter of the fetal head (Figures 5 and 6). 13 
pups born to ZIKV-infected dams were normal, while 10 pups were adversely affected. One 
ZIKV-infected dam delivered a litter of dead pups around the time of her expected due date 
Figure 5. Morphological evaluation of guinea pig pups within 24 hours of birth. (A) 
Mock pups all showed similar size in both CRL length and OF diameter. (B) Pups born to 
infected dams showed a variation in both CRL length and OF diameter. (C-D) Pups collected 
from dams euthanized due to excessive bleeding. Black arrows indicate necrosis due to 
reabsorption of fetuses. 
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(Figure 5C). Another ZIKV-infected dams had profuse bleeding two weeks before her expected 
due date and was euthanized (Figure 5D). This dam began to reabsorb some fetuses, resulting in 
tissue necrosis as seen in figure 5D. Progesterone levels were measured throughout the 
pregnancy and both females showed elevated levels until the time of euthanasia. Overall, pups 
from ZIKV-infected dams were smaller than their mock-infected counterparts. Pups from ZIKV-
infected dams exhibited significant intrauterine growth restriction (IUGR). 
Guinea pig pups born to ZIKV-infected females exhibited intrauterine growth restriction 
Along with analyzing the pups for morphological abnormalities, measurements were taken 
including pup size (Figure 6A), head circumference (Figure 6B), and weight (Figure 6C). When 
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looking at overall size using the crown-rump length and the occipito-frontal diameter, there was 
a decrease in size of the pups born to infected dams, as well as head circumference. The head 
circumference is significantly decreased compared to the mock. Similarly, there was a trend 
towards lower weight in ZIKV-infected pups, but it was not statistically significant. One aspect 
to take into consideration when looking at pup size is the litter size (Figure 6D). The smaller the 
litter the more room the fetuses have to grow because the space is not as restricted. However, 
when comparing the litter size to the pup size it was noticed that the litters born to the infected 
females were on average smaller than the control females, as well as the pup size. Overall, there 
are fewer pups per animal in ZIKV-infected cohort than mock-infected cohort and the sizes of 
the pups born to infected females were significantly smaller. The pups that exhibited the smallest 
sizes and IUGR were born to ZIKV infected females who had the most weight loss, the highest 
levels of both circulating ZIKV RNA and NS1 protein, as well as the highest levels of ZIKV-
specific antibodies. 
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Figure 7. ZIKV-specific antibody and ZIKV viral RNA detected in pups born to ZIKV 
infected dams. (A) ZIKV-specific antibodies were detected in all pups born to ZIKV infected 
dams at the time of birth using PRNT. (B) ZIKV viral RNA was detected in the brains of the 
pups born to ZIKV infected dams using qRT-PCR. 
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ZIKV-specific antibodies and viral load in pups 
At the time of euthanasia, blood was collected from the guinea pig pups to analyze for ZIKV-
specific antibodies. Anti-ZIKV antibodies were also detected in all of the pups from the ZIKV 
challenged dams (Figure 7A), suggesting that maternal antibodies to ZIKV are transmitted 
transplacentally. The pups with the highest levels of antibodies were born to the females with the 
weight loss, and showed high viremia and high antibody production.  
ZIKV RNA was analyzed from the brains of the pups born to infected females (Figure 7B). 
Other tissues such as spleen, kidney, and liver were also analyzed; however, ZIKV RNA was 
First infection (CT value) Re-infection (CT value) Result
Mock
GP 7a brain 37.42 40.8 Negative
GP 7b brain 36.5 38.37 Negative
GP 31a brain 34.8 39.8 Negative
ZIKV
GP2a 41.07 32.31 Positive
GP2b 23.26 11.39 Positive
GP2c 35.42 33.19 Negative
GP5a 31.79 24.53 Positive
GP8a 37.57 28.14 Positive
GP8b 38.16 32.04 Positive
GP6a 38.92 34.41 Negative
GP6b 41.82 30.58 Positive
GP9a 41.6 31.56 Positive
GP 9b 36.22 38.27 Negative
GP 9c 35.43 36.65 Negative
Table 2. ZIKV detection in pups brain using virus culture. Infectious viral RNA was 
recovered from brain tissue of more than 50% of guinea pig pups born to infected dams 
while there was not any viral RNA recovered from the pups born to mock dams. 
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detected only in the brain tissue. Genome copies ranged from 5.0 x 102 copies/μg to 4.0 x 104 
copies/μg in 50% of the pups born to ZIKV-infected females. The pups with the highest levels 
were born to the females with the weight loss at the time of infection, as well as the increased 
levels of ZIKV RNA, NS1 protein, and ZIKV-specific antibodies in the blood. The tissues from 
female guinea pigs were also analyzed for ZIKV RNA, however, no RNA was detected. Since 
guinea pigs have a long gestation period, about 40 days, ZIKV infection may have resolved prior 
to birth. We also conducted viral detection on Vero cells using pups brain homogenates, and the 
results showed that infectious ZIKV were directly recovered from eight out of twenty-three brain 
samples. 
ZIKV detection in pups brain using virus culture 
Since viral RNA was found in the brains of guinea pig pups using qRT-PCR, a virus detection 
was completed using brain homogenate and vero cells (Table 2). The CT values are compared to 
a standard curve of previously titrated ZIKV dilutions. ZIKV was directly recovered from more 
than 50% of the pups. The pups born to mock dams did not have any viral RNA detected. The 
results show that not all pups in the same litter had ZIKV RNA recovered from the brain tissue, 
which is consistent with what has been observed throughout the study. 
 
Discussion 
Prior to the 2015 ZIKV outbreak in Brazil, as well as other areas in Central and South America, 
only a few animal studies with ZIKV were completed, and all used mice as animal model [10, 
11]. While mice are generally a good model to use due to their small size, they may not be an 
ideal animal to study ZIKV infections since the virus cannot cause disease unless a genetic 
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knockout mouse model is used. Following the outbreak, there was an increased need for animal 
research, and animal models that do not require manipulation and resemble human infection 
were in demand. The pregnant guinea pig model used in this study provides easily measurable 
congenital abnormality readout to assess fetal outcome, and for studying the mechanisms of 
ZIKV congenital pathogenesis, all without having the need to manipulate the host’s 
immunological status. 
 
Previous studies using the guinea pig model reported clinical signs, such as fever, ruffled fur, and 
hunched back after infection with the Asian strain of ZIKV [18, 19]. Our study did not observe 
these same clinical signs. Kumar et al. infected the guinea pigs through subcutaneous route; 
however, the guinea pigs were at a younger age (5 weeks) than in this experiment (about 10 
weeks). Age is important for experimental design for a number of reasons. Studies have shown 
that young animals are still developing, making them more susceptible to infection, than their 
middle-age counterparts [22-25]. Even though our ZIKV infected guinea pigs did not show the 
same clinical signs as previously exhibited, four of the dams did lose weight as compared to the 
mock and the five additional ZIKV infected dams. The dams with weight loss exhibited the 
highest levels of ZIKV RNA in whole blood, NS1 protein in the serum, and a robust ZIKV-
specific antibody production. Following birth, the pups that exhibited abnormalities were born to 
the dams who had lost weight after infection. 
Pregnancy outcomes following ZIKV infection have been reported with various abnormalities 
including miscarriage, fetal loss, stillbirths, small size for gestational age and microcephaly [26, 
27]. ZIKV infection of pregnant guinea pigs results in a fetal syndrome that resembles the 
intrauterine growth restriction (IUGR) observed in ZIKV-infected pregnant women. ZIKV RNA 
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and anti ZIKV-antibody levels in the dam reliably predicted fetal abnormalities since the pups 
exhibiting IUGR were born to the dams most affected by ZIKV infection. Anti-ZIKV antibodies 
detected in all of the pups from the ZIKV infected dams suggest that maternal antibodies to 
ZIKV are transmitted transplacentally. Viral RNA in brain tissue and from virus culture was 
detected in around 50% of pups, correlating with the fetal abnormalities. Since the pups that 
exhibited IUGR were born to the dams most affected by the ZIKV, we are able to predict the 
outcome of the pregnancy based on the dam’s status. 
The male guinea pigs that were housed with infected female guinea pigs developed a robust 
amount of ZIKV-specific neutralizing antibodies. It was not determined at what point or through 
which route the virus was transmitted but at the time of euthanasia they ZIKV antibodies were 
detected in the serum. Since the females have the vaginal plug and do not allow intercourse 
during pregnancy, sexual transmission is not thought to be the route. Urine and saliva were also 
collected and ZIKV was detected in the urine of the females by RT-PCR during the first week 
after infection. The male guinea pigs were observed ingesting and being exposed to the urine, 
causing us to suspect that this was the route of transmission. 
 
This small animal model for ZIKV may serve as a good model to test prophylactic and 
therapeutic interventions to protect the fetus during pregnancy, as well as to study related 
flaviviruses such as dengue virus.  
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4.1 Summary: 
Zika virus (ZIKV) is an arbovirus that has been known to cause a “Zika” rash, along with mild 
flu-like symptoms. While the virus was not a major concern for many decades, with the recent 
2015 outbreak in the America’s, there was an association of ZIKV and microcephaly, as well as 
other birth defects. It is with this association that the virus became a public health concern, due 
to the lack of prophylactic and therapeutic interventions, as well as a lack of research on the 
pathogenesis of the virus. Only a few experiments had been completed prior to the outbreak 
using mice as animal models.  However, mice are not ideal due to the immunologic manipulation 
required for the virus to produce disease.  
A need for an animal model that represents human pathogenesis sparked many experiments 
analyzing various genetic knockouts of mice and hamsters, as well as the use of non-human 
primates and pigs. However, these animal models also have shortcomings.  
Previous studies using the guinea pig model reported clinical signs, such as fever, ruffled fur, and 
hunched back after infection with the Asian strain of ZIKV [34, 38]. Our study did not observe 
these same clinical signs. Kumar et al. infected the guinea pigs through subcutaneous route; 
however, the guinea pigs were at a younger age (5 weeks) than in this experiment (about 10 
weeks). Age is important for experimental design for a number of reasons. Studies have shown 
that young animals are still developing, making them more susceptible to infection, than their 
middle-age counterparts [41-44]. Even though our ZIKV infected guinea pigs did not show the 
same clinical signs as previously exhibited, four of the dams did lose weight as compared to the 
mock and the five additional ZIKV infected dams. The dams with weight loss exhibited the 
highest levels of ZIKV RNA in whole blood, NS1 protein in the serum, and a robust ZIKV-
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specific antibody production. Following birth, the pups that exhibited abnormalities were born to 
the dams who had lost weight after infection. 
Pregnancy outcomes following ZIKV infection have been reported with various abnormalities 
including miscarriage, fetal loss, stillbirths, small size for gestational age and microcephaly [10, 
45]. ZIKV infection of pregnant guinea pigs results in a fetal syndrome that resembles the 
intrauterine growth restriction (IUGR) observed in ZIKV-infected pregnant women. ZIKV RNA 
and anti ZIKV-antibody levels in the dam reliably predicted fetal abnormalities since the pups 
exhibiting IUGR were born to the dams most affected by ZIKV infection. Anti-ZIKV antibodies 
detected in all of the pups from the ZIKV infected dams suggest that maternal antibodies to 
ZIKV are transmitted transplacentally. Viral RNA in brain tissue and from virus culture was 
detected in around 50% of pups, correlating with the fetal abnormalities. Since the pups that 
exhibited IUGR were born to the dams most affected by the ZIKV, we are able to predict the 
outcome of the pregnancy based on the dam’s experimental results. 
The male guinea pigs that were housed with infected female guinea pigs developed a robust 
amount of ZIKV-specific neutralizing antibodies. It was not determined at what point or through 
which route the virus was transmitted but at the time of euthanasia they had a continued 
production of antibodies. Since the females have the vaginal plug and do not allow intercourse 
during pregnancy, sexual transmission is not thought to be the route. Urine and saliva were also 
collected and ZIKV was detected in the urine of the females by RT-PCR during the first week 
after infection. The male guinea pigs were observed licking and being exposed to the urine, 
suggesting the route of transmission. 
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It is with our guinea pig experiment that we have found an animal model that represents human 
pathogenesis with no immunologic manipulation, that is small, and relatively inexpensive to 
house and care for the animals. 
 
4.2 Future Directions: 
 
The immunologically unmanipulated pregnant guinea pig model of ZIKV infection provides 
easily measurable congenital abnormality readout to assess fetal outcome. Future studies using 
this animal model should enable testing of prophylactic and therapeutic interventions to protect 
the fetus during pregnancy, as well as studying the mechanisms of ZIKV congenital 
pathogenesis. The next important step is to elucidate the immunological mechanisms of disease 
pathogenesis. Now that we know the virus causes disease in guinea pigs and where the virus may 
be found, it is important to examine how the virus is causing the disease, which cell receptors it 
uses to gain access on the various cell types, and how the immune system function to neutralize 
the virus. Observational analysis of guinea pig pup development following birth may help to 
understand the effects of disease of children born to infected pregnant mothers. 
Further questions may be asked from this project such if antibody levels in the dams correlate 
with microcephaly and IUGR. If the antibody response is poor and not protecting efficiently 
against the virus it has potential to cause a more serious outcome. This could help predict the 
child’s outcome prior to birth based on the antibody response produced by the mothers who had 
been infected during pregnancy. 
Insights gained from these studies should facilitate the development of vaccines and anti-virals. 
Such prophylactic and therapeutic interventions are urgently needed due to the significant 
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disease complications, such as Congenital Zika Syndrome, caused by ZIKV as discovered from 
the 2015 outbreak in the America’s.  
Furthermore, this animal model may be used for other closely related flaviviruses, such as 
dengue virus. There have been recent experiments examining the relation between dengue virus 
and Zika virus in terms of severity of disease, as well as association with Congenital Zika 
Syndrome. The guinea pig model would provide an unmanipulated model to represent human 
pathogenesis to determine the relation between these two flaviviruses.  
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